Time filter

Source Type

Città della Pieve, Italy

Mariscotti G.,University of Turin | Houssami N.,Screening and Test Evaluation Program | Durando M.,University of Turin | Bergamasco L.,University of Turin | And 8 more authors.
Anticancer Research | Year: 2014

Aim: To define the accuracy of digital breast tomosynthesis (DBT) and magnetic resonance imaging (MRI) added to digital mammography (DM) and ultrasound (US) in the preoperative assessment of breast cancer. Patients and Methods: We performed a prospective study of 200 consecutive women with histologically-proven breast cancer using the above imaging techniques. Accuracy measurements were estimated using a lesion-by-lesion analysis for unifocal, multifocal/multicentric, bilateral and all carcinomas. We also calculated sensitivity according to breast density. Results: DBT had higher sensitivity than DM (90.7% vs. 85.2%). Combined DM and DBT with US yielded a 97.7% sensitivity; despite high sensitivity of MRI (98.8%), the addition of MRI to combined DM with DBT and US did not significantly improve sensitivity. Overall accuracy did not significantly differ between MRI and DM with DBT and US (92.3% vs. 93.7%). Breast density affected sensitivity of DM and DBT (statistically significant difference for DM), not MRI. Conclusion: There is little gain in sensitivity and no gain in overall accuracy, by performing MRI for patients who have been evaluated with DM with DBT and US. Source

Hou P.,Northeast Normal University | Zhao Y.,Northeast Normal University | Li Z.,Key Laboratory of Molecular Epigenetics of Ministry of Education MOE | Yao R.,Northeast Normal University | And 6 more authors.
Cell Death and Disease | Year: 2014

LncRNAs have critical roles in various biological processes ranging from embryonic development to human diseases, including cancer progression, although their detailed mechanistic functions remain illusive. The lncRNA linc-ROR has been shown to contribute to the maintenance of induced pluripotent stem cells and embryonic stem cells. In this study, we discovered that linc-ROR was upregulated in breast tumor samples, and ectopic overexpression of linc-ROR in immortalized human mammary epithelial cells induced an epithelial-to-mesenchymal transition (EMT) program. Moreover, we showed that linc-ROR enhanced breast cancer cell migration and invasion, which was accompanied by generation of stem cell properties. Contrarily, silencing of linc-ROR repressed breast tumor growth and lung metastasis in vivo. Mechanistically, our data revealed that linc-ROR was associated with miRNPs and functioned as a competing endogenous RNA to mi-205. Specifically, linc-ROR prevented the degradation of mir-205 target genes, including the EMT inducer ZEB2. Thus our results indicate that linc-ROR functions as an important regulator of EMT and can promote breast cancer progression and metastasis through regulation of miRNAs. Potentially, the findings of this study implicate the relevance of linc-ROR as a possible therapeutic target for aggressive and metastatic breast cancers. © 2014 Macmillan Publishers Limited All rights reserved. Source

He Y.-J.,Xuzhou Medical College | Wu J.-Z.,Center Laboratory | Ji M.-H.,Jiangsu Cancer Hospital | Ma T.,Nanjing Medical University | And 3 more authors.
Experimental and Therapeutic Medicine | Year: 2013

Estrogen receptor-α (ERα) is essential for estrogen-dependent growth and its level of expression is a crucial determinant of response to endocrine therapy and prognosis in ERα-positive breast cancer. Breast cancer patients show a wide range of ERα expression levels which change in individual patients during disease progression and in response to systemic therapies. However, little is known concerning how the expression of ERα is regulated in human breast cancer. Recently, several microRNAs (miRNAs) have been identified to regulate ERα expression and to predict ER, progesterone receptor (PR) and human epidermal growth factor 2 (HER2) status. The expression levels of miR-342 and ERα mRNA were analyzed in human breast cancer samples and cell lines by quantitative reverse transcription (RT)-PCR analysis. The correlations between the expression levels of miR-342 and clinicopathological factors were analyzed. Statistically significant associations were observed between miR-342 and ER, HER2 and vascular endothelial growth factor (VEGF) status in the human breast cancer samples and the levels of miR-342 gradually increased as ERα mRNA expression increased. Moreover, ectopic overexpression of miR-342 upregulated the expression levels of the ERα mRNA and significantly sensitized the MCF-7 cells to tamoxifen-induced apoptosis and inhibition of cellular proliferation. These results suggested that miR-342 expression is positively correlated with ERα mRNA expression in human breast cancer and that it may be a significant marker for predicting tamoxifen sensitivity in ERα-positive breast cancer and a potential target for restoring ERα expression and responding to antiestrogen therapy. Source

Liu G.,Fuyang Teachers College | Yu G.,Breast Surgery | Fan S.,Fuyang Teachers College
Jisuan Wuli/Chinese Journal of Computational Physics | Year: 2015

Dielectric properties of a variety of media, such as biological tissues, soil, and water, are frequency-dependent, which are depicted frequently by a single-pole Debye model. A three-dimensional (3-D) time-domain electromagnetic inverse scattering technique, based on functional analysis and variation method, is developed to reconstruct dispersive properties of media. Main procedures of the technique are: (1) Inverse scattering problem is turned into a constrained minimization problem, according to the least squares criterion; (2) Resulting problem is translated into an unconstrained minimization one, using a penalty function method; (3) Closed Fréchet derivatives of Lagrange function with respect to properties are derived, based on calculus of variations; (4) Resulting problem is solved with any gradient-based algorithm. Furthermore, a first-order Tikhonov's regularization is adopted to cope with noise and ill-posedness of the problem. In numerical experiment, the technique is applied to a simple 3-D cancerous breast model, with Polak-Ribière-Polyak conjugate gradient algorithm and finite-difference time-domain method. Simulated results demonstrate preliminarily feasibility, effectiveness and robustness of the method. ©, 2015, Chinese Nuclear Society. All right reserved. Source

Introduction. We present the case of a 40-year-old man with severe rheumatoid arthritis being treated with high-dose anti-tumor necrosis factor α therapy (adalimumab), who developed simultaneous lymphoma and breast cancer with lymph node metastases. We describe strategies for investigations and management of this presentation. Case presentation. A 40-year-old Caucasian man with severe rheumatoid arthritis being treated with high-dose adalimumab presented to our facility with a swollen leg and palpable left groin and left axillary lumps and a left nipple lesion. Left lower limb ultrasound, computed tomography and positron emission tomography scans showed extensive lymphadenopathy. Core biopsies of the left groin, axilla and nipple lesion showed this to be concurrent diffuse B-cell lymphoma and locally metastatic invasive ductal carcinoma of the breast. He underwent a left mastectomy with axillary clearance, and adjuvant fluorouracil, epirubicin and cyclophosphamide chemotherapy with rituximab, and the adalimumab was stopped. Conclusions: The findings from our patient's case should increase awareness that patients with severe rheumatoid arthritis, especially if they are on high-dose biological treatments, have the potential to develop lymphoma, which in turn increases the risk of developing other primary tumors, so that in rare cases a patient may have concurrent tumors. Assessment and management of these patients is challenging and should include computed tomography scans of the of neck, thorax, abdomen and pelvis, including a fludeoxyglucose positron emission tomography/computed tomography scan, bone marrow testing and appropriate core biopsies and discussion at multidisciplinary team meetings about treatment of the separate tumors in the presence of hematologists, oncologists, surgeons and rheumatologists. © 2013 Datta and Maisnam; licensee BioMed Central Ltd. Source

Discover hidden collaborations